Compare Dishman Pharma with Piramal Enterprises - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA PIRAMAL ENTERPRISES DISHMAN PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 25.1 -42.2 - View Chart
P/BV x 3.3 1.4 235.2% View Chart
Dividend Yield % 0.7 1.6 40.8%  

Financials

 DISHMAN PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
PIRAMAL ENTERPRISES
Mar-19
DISHMAN PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3743,303 11.3%   
Low Rs1291,797 7.2%   
Sales per share (Unadj.) Rs197.8716.5 27.6%  
Earnings per share (Unadj.) Rs21.279.7 26.6%  
Cash flow per share (Unadj.) Rs34.7107.9 32.2%  
Dividends per share (Unadj.) Rs2.0028.00 7.1%  
Dividend yield (eoy) %0.81.1 72.4%  
Book value per share (Unadj.) Rs179.91,477.5 12.2%  
Shares outstanding (eoy) m80.69184.45 43.7%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x1.33.6 35.8%   
Avg P/E ratio x11.932.0 37.1%  
P/CF ratio (eoy) x7.223.6 30.7%  
Price / Book Value ratio x1.41.7 81.1%  
Dividend payout %9.435.1 26.8%   
Avg Mkt Cap Rs m20,306470,292 4.3%   
No. of employees `0000.87.8 10.6%   
Total wages/salary Rs m5,35522,504 23.8%   
Avg. sales/employee Rs Th19,252.716,899.4 113.9%   
Avg. wages/employee Rs Th6,459.52,877.7 224.5%   
Avg. net profit/employee Rs Th2,064.11,879.9 109.8%   
INCOME DATA
Net Sales Rs m15,961132,153 12.1%  
Other income Rs m2653,128 8.5%   
Total revenues Rs m16,226135,281 12.0%   
Gross profit Rs m4,10366,290 6.2%  
Depreciation Rs m1,0915,202 21.0%   
Interest Rs m94444,097 2.1%   
Profit before tax Rs m2,33420,119 11.6%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6248,611 7.2%   
Profit after tax Rs m1,71114,701 11.6%  
Gross profit margin %25.750.2 51.3%  
Effective tax rate %26.742.8 62.4%   
Net profit margin %10.711.1 96.4%  
BALANCE SHEET DATA
Current assets Rs m11,018122,742 9.0%   
Current liabilities Rs m9,517310,810 3.1%   
Net working cap to sales %9.4-142.3 -6.6%  
Current ratio x1.20.4 293.2%  
Inventory Days Days11023 479.0%  
Debtors Days Days3539 89.7%  
Net fixed assets Rs m16,304116,904 13.9%   
Share capital Rs m161369 43.8%   
"Free" reserves Rs m12,907272,161 4.7%   
Net worth Rs m14,516272,530 5.3%   
Long term debt Rs m4,189270,196 1.6%   
Total assets Rs m29,805856,261 3.5%  
Interest coverage x3.51.5 238.4%   
Debt to equity ratio x0.31.0 29.1%  
Sales to assets ratio x0.50.2 347.0%   
Return on assets %8.96.9 129.7%  
Return on equity %11.85.4 218.5%  
Return on capital %17.512.4 141.1%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95215,200 32.6%   
Fx outflow Rs m6974,889 14.3%   
Net fx Rs m4,25510,312 41.3%   
CASH FLOW
From Operations Rs m2,786-115,975 -2.4%  
From Investments Rs m-1,529-8,265 18.5%  
From Financial Activity Rs m-941107,525 -0.9%  
Net Cashflow Rs m316-16,650 -1.9%  

Share Holding

Indian Promoters % 61.4 52.9 116.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 4.0 92.5%  
FIIs % 12.7 26.6 47.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 16.5 133.9%  
Shareholders   46,261 93,274 49.6%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  DR. REDDYS LAB  TORRENT PHARMA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS